Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Denka Seiken to Develop Intradermal Flu Vaccine
March 16, 2016
- J-TEC to Venture into CRO Biz for Regenerative Medicine
March 16, 2016
- Takeda Spins Out Investigational Stress Urinary Incontinence Drug to Yamada-Led US Firm
March 16, 2016
- Ethical Drug Sales Up 7.0% in January: Crecon Report
March 15, 2016
- Lilly Seeks to Block Launch of Evista Generics Approved in February
March 15, 2016
- AbbVie Launches Japan PIII Trials for All Hep C Genotypes
March 15, 2016
- MSD Files 2 Antivirals for Hep C Treatment in Japan
March 14, 2016
- Ono Beefing Up Organization for Safe Use of Opdivo, Eyes Larger Cancer Sales Force
March 11, 2016
- Mitsubishi Tanabe to Solely Market Janssen’s Simponi in Japan
March 11, 2016
- Takecab Most Heavily Pitched Drug in January: Anterio
March 11, 2016
- Re-Pricing, Z2, Deferred Price Cuts Hammering Mainstay Drugs, Otsuka Sees Double-Digit Reductions for Top 5 Sellers: Tally
March 9, 2016
- Japan Generic Market to Reach 1.1 Trillion Yen in 2018: Fuji Keizai
March 9, 2016
- Nemolizumab Shows Efficacy for Atopic Dermatitis in Global PII: Chugai
March 8, 2016
- Sandoz Suffers Hefty 20% Price Cuts in FY2016 Revision, Teva 8.3%: Jiho Survey
March 8, 2016
- Kyowa Kirin Expects to Double Sales Force in US to Build Independent Marketing System; Anticipates Launch of Parkinson’s Drug in 2018
March 8, 2016
- Toyama Chemical Sues 3 Generic Firms over Ozex Patent
March 8, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
- Z2 Price Cut Rule to Smash Mitsubishi Tanabe, Astellas, Pfizer: Jiho Tally
March 7, 2016
- Drug Price Cut to Net Out at 5.5% for Chugai, Gilead to Suffer 31.65% in Full: Jiho Tally
March 7, 2016
- Japan NDA Filed for Anti-HIV Drug Genvoya
March 7, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…